How long does Nplate (romiplostim) take to work?
Nplate (romiplostim) starts working from the first dose to increase platelet counts. In a clinical study of 75 adults with immune thrombocytopenia (ITP), the median time to first platelet response was 2.1 weeks. Other studies have reported 4-9 days until Nplate took effect in healthy individuals.
How Is Nplate Dosed?
Nplate (romiplostim) is a biological drug given by subcutaneous (under the skin) injection once a week to treat immune thrombocytopenia (low blood platelet counts). Nplate works to boost the body's production of platelets.
The lowest dose possible of Nplate should be used to achieve and maintain a platelet count of greater than or equal to 50 x 109/L.
- The initial dose is 1 mcg/kg per week, adjusted in 1 mcg/kg increments to maintain a platelet count of ≥50 x 10⁹/L.
- The maximum dose is 10 mcg/kg per week.
- If platelet counts do not increase after four weeks at the maximum dose, treatment should be discontinued.
How Effective Is Nplate?
Platelet counts typically increase over 2–3 weeks following the first dose. One study found that the onset of action of Nplate to increase platelets took about 4-9 days, and the peak platelet counts were reached around days 12-16.
In clinical studies, adult patients who responded to treatment with Nplate and achieved and maintained the desired platelet count did so on a median dose of 2-3 mcg/kg of Nplate a week.
Other Uses of Nplate
Nplate is also approved for hematopoietic syndrome of acute radiation syndrome (ARS) as a one-time treatment to increase survival.
This is not all the information you need for the safe and effective use of Nplate. Always consult your healthcare provider for personalized medical advice.
References
- Food and Drug Administration (FDA). Nplate. February 2021. [Accessed August 16, 2021]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125268s168lbl.pdf.
- Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016;172(2):262-273. doi:10.1111/bjh.13827.
- Wang, B., et. al. 2004. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. In: Clinical Pharmacology and Therapeutics. DOI: https://doi.org/10.1016/j.clpt.2004.08.010
Related medical questions
- How is Nplate (romiplostim) administered?
- Is Nplate a chemotherapy drug?
- What is Nplate used for and how does it work?
- Does Nplate cause hair loss?
- Prednisone: What are 12 Things You Should Know?
- What is Doptelet used for and how does it work?
- How long does it take for Gamunex-C to work?
Drug information
Related support groups
- Nplate (5 questions, 13 members)
- Romiplostim (4 questions, 5 members)
- Idiopathic (Immune) Thrombocytopenic Purpura (10 questions, 54 members)